Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males, \>=12 years of age.~* Severe hemophilia A or B (as evidenced by a central laboratory measurement at screening or documented medical record evidence of FVIII less than (\<) 1 percent (%) or FIX level less than or equal to (\<=) 2%).~* A minimum of 2 bleeding episodes required BPA treatment within the last 6 months prior to screening for participants with inhibitory antibodies to factor VIII or factor IX (Cohort A). A minimum of 1 bleeding episode required factor treatment within the last 12 months prior to screening for participants without inhibitory antibodies to factor VIII or factor IX (Cohort B).~* Met either the definition of inhibitor or non-inhibitor participant as below:~* Inhibitor: Use of BPAs for prophylaxis and for any bleeding episodes for at least the last 6 months prior to screening, and met one of the following Nijmegen-modified Bethesda assay results criteria:~* Inhibitor titer of \>=0.6 Bethesda Unit per milliliter (BU/mL) at screening, or~* Inhibitor titer of \<0.6 BU/mL at screening with medical record evidence of 2 consecutive titers \>=0.6 BU/mL, or~* Inhibitor titer of \<0.6 BU/mL at screening with medical record evidence of anamnestic response~* The subgroup of participants in Cohort A participants might additionally meet the following criteria to be eligible to start treatment with fitusiran directly after the screening period:~  * Hemophilia B with inhibitory antibody to Factor IX as defined above~ * Not responding adequately to BPA treatment (historical ABR \>=20) prior to enrollment~ * In the opinion of the Investigator, with approval of Sponsor Medical Monitor, 6-month BPA prophylaxis period should be omitted.~* Non-inhibitor: Use of factor concentrates for prophylaxis and for any bleeding episodes for at least the last 6 months prior to screening, and met each of the following criterion:~* Nijmegen-modified Bethesda assay inhibitor titer of \<0.6 BU/mL at screening and~* No use of BPAs to treat bleeding episodes for at least the last 6 months prior to screening and~* No history of immune tolerance induction therapy within the past 3 years prior to screening.~* Documented prophylactic treatment with factor concentrates or BPAs for the treatment of hemophilia A or B for at least 6 months prior to screening.~* Adherent to the prescribed prophylactic therapy for at least 6 months prior to screening per Investigator assessment.~* Willed and complied with the study requirements and to provide written informed consent and assent.~Exclusion Criteria:~* Known co-existing bleeding disorders other than hemophilia A or B.~* AT activity \<60% at screening.~* Co-existing thrombophilic disorder.~* Clinically significant liver disease.~* Active Hepatitis C virus infection.~* Acute or chronic Hepatitis B virus infection.~* HIV positive with a CD4 count of \<200 cells per microliter.~* History of arterial or venous thromboembolism.~* Inadequate renal function.~* History of multiple drug allergies or history of allergic reaction to an oligonucleotide or N-Acetylgalactosamine (GalNAc).~* History of intolerance to subcutaneous injection(s).~* Any other conditions or comorbidities that made the participant unsuitable for enrollment or could interfere with participation in or completion of the study, per Investigator judgment.

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fitusiran (Type: EXPERIMENTAL): Cohort A \[inhibitor\]: participants with severe hemophilia A/B and inhibitory antibodies to coagulation factor VIII (FVIII)/factor IX (FIX) previously received BPA prophylaxis. Cohort B \[non-inhibitor\]: participants with severe hemophilia A/B without inhibitory antibodies to FVIII/FIX previously received factor prophylaxis. Participants from both cohorts was enrolled into 6-month factor/BPA prophylaxis period and continued their pre-study, regularly scheduled prophylaxis regimen with factor/BPAs. This period could be skipped by subgroup of Cohort A (hemophilia B with inhibitors to FIX and historical annualized bleeding rate \[ABR\] \>=20) that started directly with fitusiran. Post completing factor/BPA prophylaxis period, participants entered 7-month fitusiran treatment period (1-month onset+6-month efficacy) followed by AT follow-up/roll-over into LTE15174 (NCT03754790). Throughout study, participants could receive on-demand treatment for breakthrough BE with factor/BPAs, as appropriate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete